247 related articles for article (PubMed ID: 24584921)
1. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.
Akkineni R; Tapp S; Tosteson AN; Lee A; Miller KL; Choi HK; Zhu Y; Albert DA
J Rheumatol; 2014 Apr; 41(4):739-48. PubMed ID: 24584921
[TBL] [Abstract][Full Text] [Related]
2. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
3. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
4. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
5. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
[TBL] [Abstract][Full Text] [Related]
6. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
7. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
10. [Hyperuricemia].
Chizyński K; Rózycka M
Pol Merkur Lekarski; 2005 Nov; 19(113):693-6. PubMed ID: 16498814
[TBL] [Abstract][Full Text] [Related]
11. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
12. Impact of allopurinol use on urate concentration and cardiovascular outcome.
Wei L; Mackenzie IS; Chen Y; Struthers AD; MacDonald TM
Br J Clin Pharmacol; 2011 Apr; 71(4):600-7. PubMed ID: 21395653
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Fujimori S
Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
[TBL] [Abstract][Full Text] [Related]
14. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study.
Larsen KS; Pottegård A; Lindegaard HM; Hallas J
Am J Med; 2016 Mar; 129(3):299-306.e2. PubMed ID: 26589484
[TBL] [Abstract][Full Text] [Related]
15. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.
Saddekni MB; Saag KG; Dudenbostel T; Oparil S; Calhoun DA; Sattui SE; Feig DI; Muntner P; Redden DT; Foster PJ; Rahn EJ; Biggers SR; Li P; Gaffo AL
Contemp Clin Trials; 2016 Sep; 50():238-44. PubMed ID: 27587282
[TBL] [Abstract][Full Text] [Related]
16. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
[TBL] [Abstract][Full Text] [Related]
18. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
[TBL] [Abstract][Full Text] [Related]
20. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Wortmann RL; Macdonald PA; Hunt B; Jackson RL
Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
